Russia to tighten control for foreign medical labs and pharma companies

Russia can tighten a control on foreign medical laboratories and pharmaceutical companies, operating in the domestic market, according to the press-service of the Russian government and sources in the country’s special services.

That will be mainly due to their intensified activities for the conduct of clinical trials in Russia and associated with this collection of data about Russian patients, including biomaterials, reports The Pharma Letter’s local correspondent.

This has already sparked concerns from the state, while the national government has already announced its plans to submit a bill to the State Duma (Parliament), aimed at ensuring the biological safety of Russians, according to recent statements by former Russian chief sanitary officer of Russia Gennady Onishchenko, who currently holds a position of the first deputy chairman of the committee for education and science of the Russian State Duma.